Entrada Therapeutics, Inc.

TRDA

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001689375

SEC filings (opens in a new tab)

In the last 90 days, Entrada Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 128 institutions reported holding it in 13F filings for Q2 2026, worth $214.4M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 9, 2026: $183.6M
Insider buysOpen market, last 90 days: 0
Insider sellsLast 90 days, $3.60M in total: 4
13F holdersQ2 2026, +10 vs. previous quarter: 128
13F valueReported value at the end of Q2 2026: $214.4M
Superinvestors holdingAt the end of Q2 2026: 0

Price chart

Chart by TradingView (opens in a new tab)

Financials

See financial statements

From SEC filings, in USD.

Revenue, FY2025: $25.4M; −87.9% year over year
Net income, FY2025: -$143.8M; −319.0% year over year
Free cash flow, FY2025: -$129.6M; No comparable prior period
Revenue, Q3 FY2026: $905.0K; −43.9% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $143.8M (565.5% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 15, 2026.

Short interest: 3.27M; Shares sold short
Change: +282.3K; +9.4% vs. previous
Days to cover: 8.60; At average daily volume

Superinvestors holding TRDA, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding TRDA at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Entrada Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Sep 9, 2026 (view filing)7:24 PM ET	Sep 4-9	5 days	MPM Bioventures 2018, L.P. and 2 others10% Owner	SSale	−259.8K	$7.33	−$1.91M	−6.3%3.89M after	3 lotsDuplicate filing
Sep 9, 2026 (view filing)7:23 PM ET	Sep 4-9	5 days	Gadicke Ansbert and 9 others10% Owner	SSale	−259.8K	$7.33	−$1.91M	−6.3%3.89M after	3 lots
Sep 3, 2026 (view filing)7:21 PM ET	Sep 1-3	2 days	MPM Bioventures 2018, L.P. and 2 others10% Owner	SSale	−86.5K	$7.14	−$617.4K	−2.0%4.14M after	3 lotsDuplicate filing
Sep 3, 2026 (view filing)7:21 PM ET	Sep 1-3	2 days	Gadicke Ansbert and 9 others10% Owner	SSale	−86.5K	$7.14	−$617.4K	−2.0%4.14M after	3 lots
Aug 31, 2026 (view filing)6:26 PM ET	Aug 27-31	4 days	MPM Bioventures 2018, L.P. and 2 others10% Owner	SSale	−86.9K	$7.08	−$615.8K	−2.0%4.23M after	3 lotsDuplicate filing
Aug 31, 2026 (view filing)6:25 PM ET	Aug 27-31	4 days	Gadicke Ansbert and 9 others10% Owner	SSale	−86.9K	$7.08	−$615.8K	−2.0%4.23M after	3 lots
Aug 26, 2026 (view filing)9:28 PM ET	Aug 24-26	2 days	Gadicke Ansbert and 9 others10% Owner	SSale	−62.7K	$7.36	−$461.5K	−1.4%4.32M after	3 lotsDuplicate filing
Aug 26, 2026 (view filing)9:27 PM ET	Aug 24-26	2 days	MPM Bioventures 2018, L.P. and 2 others10% Owner	SSale	−62.7K	$7.36	−$461.5K	−1.4%4.32M after	3 lots
Aug 10, 2026 (view filing)7:54 PM ET	Aug 6-10	4 days	Parmar KushDirector	SSale	−155.3K	$6.95	−$1.08M	−5.5%2.69M after	3 lots
Aug 10, 2026 (view filing)7:52 PM ET	Aug 6-7	4 days	Rocklage Scott M and 5 others10% Owner	SSale	−62.8K	$6.88	−$431.8K	−2.2%2.78M after	2 lots

Top 10 13F holders, Q2 2026

See all 128 holders

The largest institutional positions in Entrada Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding TRDA in Q2 2026
Institution	Shares	Value	% of portfolio	Change in shares	Action
Baker Bros. Advisors LP	5,072,730	$37.3M	0.19%	00.0%	Unchanged
5AM Venture Management, LLC	4,056,379	$29.9M	10.37%	00.0%	Unchanged
BlackRock, Inc.	2,583,333	$19.0M	0.00%	+224,540+9.5%	Added
Merck & Co., Inc.	1,739,768	$12.8M	2.43%	+1,739,768	New
Vanguard Capital Management LLC	1,269,634	$9.34M	0.00%	+13,621+1.1%	Added
MPM Oncology Impact Management LP	1,253,053	$9.22M	0.56%	+1,253,053	New
TCG Crossover Management, LLC	1,060,230	$7.80M	0.19%	−1,227,270−53.7%	Reduced
Wellington Management Group LLP	954,419	$7.02M	0.00%	−80,363−7.8%	Reduced
Millennium Management LLC	763,959	$5.62M	0.00%	+244,603+47.1%	Added
StepStone Group LP	761,277	$5.60M	0.26%	00.0%	Unchanged

Holders of 5% or more of TRDA

See all 4 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Entrada Therapeutics, Inc..

Largest holders of TRDA from 13D and 13G filings
Holder	Latest form	Stake	Change	First filed	Latest filing	Filing
5AM Ventures V, L.P.	13D/A	10.80%4.12M shares	–	Nov 12, 20212 filings	Nov 18, 2025	SEC
MPM BioVentures 2014, L.P.	13D/A	9.90%3.89M shares	–	Nov 12, 20212 filings	Sep 10, 2026	SEC
Roche Finance Ltd	13G/A	6.90%2.57M shares	–	Feb 14, 20223 filings	Feb 14, 2025	SEC
BlackRock, Inc.	13G	5.30%1.97M shares	New	Feb 4, 20251 filing	Feb 4, 2025	SEC